Skip to content
Medical Health Aged Care

RACGP applauds NSW RSV immunisation rollout

Royal Australian College of GPs 2 mins read

The Royal Australian College of GPs (RACGP) has welcomed the New South Wales Government rolling out an RSV immunisation program for at risk infants.

It comes following reports that 9,000 babies across the state most at risk from respiratory syncytial virus, or RSV, will be eligible for the vaccination from Monday. The program will initially be offered to premature infants born after 31 October last year, as well as all Aboriginal and Torres Strait Islander infants born after that same date. Other high-risk, eligible infants including those with chronic neonatal lung disease less than 12 months of age and babies with combined immunodeficiency.

Recently, the College welcomed Western Australia becoming the first Australian jurisdiction to rollout an infant RSV immunisation and  urged Tasmania to follow suit.

RACGP NSW and ACT Chair, Dr Rebekah Hoffman, welcomed the decision.

“This decision will save lives in my home state,” she said.

“Some families may not realise that RSV is the number one cause of hospitalisation for children aged five and under. So, by immunising those infants who are particularly vulnerable to severe health impacts from RSV infection, we can keep these babies as safe as possible. Well done to the New South Wales Government for rolling out this immunisation, it will make such a difference in communities across the state.”

Respiratory syncytial virus, or RSV, is common respiratory infection which mostly affects young children, including babies. The symptoms are usually mild and manageable at home; however, some children and adults can become extremely ill and require hospital treatment. There were 127,944 RSV cases reported last year Australia-wide, causing symptoms that ranged from mild to life-threatening.

~ENDS

RACGP spokespeople are available for interview.


About us:

About the RACGP

The Royal Australian College of General Practitioners (RACGP) is the peak representative organisation for general practice, the backbone of Australia’s health system. We set the standards for general practice, facilitate lifelong learning for GPs, connect the general practice community, and advocate for better health and wellbeing for all Australians.

Visit www.racgp.org.au. To unsubscribe from RACGP media releases, click here.


Contact details:

John Ronan
Media Adviser

Ally Francis
Media Adviser

Stuart Winthrope
Media Officer

 

Email: media@racgp.org.au (we will respond promptly to all media inquiries).

Follow us on Twitter: @RACGP and Facebook.

More from this category

  • Medical Health Aged Care
  • 31/10/2024
  • 17:55
Kyowa Kirin Co., Ltd.

Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company’s 2030…

  • Contains:
  • Medical Health Aged Care
  • 31/10/2024
  • 12:10
MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study,…

  • Business Company News, Medical Health Aged Care
  • 31/10/2024
  • 11:03
Firebrick Pharma

Agreement Signed to Market Nasodine to Healthcare Professionals in Singapore

Firebrick Pharmais pleased to announce that it has executed a Marketing Representation Agreement (the “Agreement”) with Singapore-based, Innorini, trading as Innorini Life Sciences (“Innorini”). The initial term of the Agreement is one year with the option to renew for subsequent one-year terms by mutual agreement. Under the Agreement, Innorini will undertake “Marketing Services” commencing 1 November 2024. The Marketing Services comprise sampling and promotion of Nasodine® Nasal Spray (“Nasodine”) to General Practitioners (“GPs”) and hospital-based doctors and pharmacists (collectively “HCPs”) in Singapore. In addition to building awareness and support of Nasodine by HCPs, Innorini will be expected to sell Nasodine…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.